Table 2 Baseline and follow-up assessment outcomes based on least-squares mean estimates of a mixed-model analysis within the complete case sample (n = 724 intervention; n = 728 control participants)
Intervention group (n = 724) | Control group (n = 728) | GroupaTime Inter-action p | Between-group differences | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Raw mean (SD) | Change to baseline | Raw mean (SD) | Change to baseline | Adjusted mean difference (95%CI) | ||||||
Outcome variables | Adjusted mean (95% CI) | p | Adjusted mean (95% CI) | p | p | ES | ||||
Primary outcomea | ||||||||||
ChEDE | ||||||||||
Baseline | 0.82 (1.08) | 0.84 (1.01) | ||||||||
6 months follow-up | 0.79 (1.07) | −0.06 (−0.17; 0.04) | .22 | 0.79 (1.07) | −0.05 (−0.16; 0.07) | 0.38 | −0.01 (−0.17; 0.14) | .85 | ||
Secondary outcomesb | ||||||||||
ChEDE | ||||||||||
Baseline | 0.82 (1.08) | 0.84 (1.01) | ||||||||
Post-intervention | 0.81 (1.10) | −0.04 (−0.12; 0.05) | .37 | 0.82 (1.02) | −0.07 (−0.16; 0.02) | 0.11 | 0.03 (−0.08; 0.15) | .54 | ||
6 months follow-up | 0.79 (1.07) | −0.05 (−0.13; 0.03) | .21 | 0.86 (1.02) | −0.03 (−0.12; 0.06) | 0.43 | 0.118 | −0.02 (−0.14; 0.10) | .77 | |
Knowledge | ||||||||||
Baseline | 8.72 (2.93) | 9.13 (2.68) | ||||||||
Post-intervention | 11.91 (3.61) | 3.12 (2.64; 3.60) | <.01 | 9.21 (2.89) | 0.12 (−0.43; 0.67) | .65 | 3.00 (2.27; 3.72) | <.01 | 1.06 | |
6 months follow-up | 10.35 (3.37) | 1.56 (1.08; 2.04) | <.01 | 9.65 (3.04) | 0.56 (0.01; 1.10) | .05 | <.001 | 1.00 (0.01; 1.73) | .01 | 0.40 |
SATAQ Internalization | ||||||||||
Baseline | 11.50 (5.96) | 11.80 (5.75) | ||||||||
Post-intervention | 11.95 (6.14) | 0.40 (−0.03; 0.82) | .07 | 11.83 (5.74) | −0.01 (−0.47; 0.45) | .97 | 0.40 (−0.22; 1.03) | .18 | ||
6 months follow-up | 11.61 (5.93) | 0.07 (−0.36; 0.49) | .75 | 12.04 (5.89) | 0.20 (−0.26; 0.65) | .37 | 0.02 | −0.13 (−0.75; 0.49) | .66 | |
SATAQ Awareness | ||||||||||
Baseline | 13.42 (4.52) | 13.89 (4.57) | ||||||||
Post-intervention | 13.83 (5.28) | 0.35 (−0.13; 0.82) | .14 | 13.89 (4.73) | 0.08 (−0.43; 0.59) | .74 | 0.27 (−0.43; 0.96) | .42 | ||
6 months follow-up | 13.51 (5.01) | 0.03 (−0.44; 0.50) | .90 | 14.12 (4.73) | 0.30 (−0.21; 0.81) | .23 | 0.02 | −0.27 (−0.96; 0.42) | .42 | |
SATAQ Pressure | ||||||||||
Baseline | 8.96 (4.74) | 9.13 (4.52) | ||||||||
Post-intervention | 10.16 (5.00) | 1.20 (0.94; 1.46) | <.01 | 9.67 (4.78) | 0.54 (0.29; 0.79) | <0.001 | 0.66 (0.31; 1.02) | <.01 | 0.10 | |
6 months follow-up | 9.66 (4.86) | 0.70 (0.44; 0.96) | <.01 | 10.08 (4.95) | 0.95 (0.69; 1.20) | <0.001 | <.001 | −0.25 (−0.61; 0.11) | .17 | |
MSCS General | ||||||||||
Baseline | 111.56 (19.28) | 111.13 (18.08) | ||||||||
Post-intervention | 111.83 (19.95) | 0.52 (−1.24; 2.28) | .54 | 112.96 (18.70) | 2.43 (0.51; 4.35) | .02 | −1.91 (−4.50; −0.68) | .13 | ||
6 months follow-up | 112.88 (20.85) | 1.57 (−0.19; 3.33) | .08 | 113.24 (19.28) | 2.71 (0.79; 4.64) | .01 | 0.36 | −1.14 (−3.74; 1.45) | .35 | |
MSCS Body Related | ||||||||||
Baseline | 46.54 (12.04) | 47.45 (11.57) | ||||||||
Post-intervention | 46.07 (11.90) | −0.48 (−1.28; 0.32) | .23 | 47.37 (11.81) | 0.56 (−0.26; 1.37) | .17 | −1.04 (−2.17; 0.09) | .07 | ||
6 months follow-up | 47.27 (12.39) | 0.72 (−0.08; 1.51) | .08 | 48.25 (11.99) | 1.44 (0.62; 2.25) | <.01 | 0.53 | −0.72 (−1.85; 0.41) | .20 | |
PHQ-9 | ||||||||||
Baseline | 5.41 (4.32) | 5.39 (4.26) | ||||||||
Post-intervention | 5.16 (4.61) | −0.16 (−0.52; 0.19) | .34 | 5.20 (3.94) | −0.25 (−0.64; 0.14) | .18 | 0.09 (−0.43; 0.61) 0.07 (−0.45; 0.59) | .73 .78 | ||
6 months follow-up | 5.28 (4.37) | −0.04 (−0.40; 0.31) | .80 | 5.34 (4.07) | −0.11 (−0.50; 0.27) | .54 | 0.92 | |||
GAD-7 | ||||||||||
Baseline | 3.90 (3.93) | 3.94 (3.86) | ||||||||
Post-intervention | 3.21 (3.94) | −0.65 (−1.00; −0.29) | <.01 | 3.95 (3.97) | −0.01 (−0.40;0.38) | .95 | −0.63 (−1.16; −0.10) | .02 | 0.22 | |
6 months follow-up | 3.62 (3.98) | −0.24 (−0.60; 0.12) | .18 | 3.92 (3.99) | −0.05 (−0.44; 0.35) | .80 | 0.01 | −0.19 (−0.72; 0.34) | .45 | |